Total Payments
$52,107
2024 Payments
$19,612
Companies
16
Transactions
90
Medicare Patients
801
Medicare Billing
$160,559
Payment Breakdown by Category
Consulting$25,572 (49.1%)
Research$11,345 (21.8%)
Travel$8,084 (15.5%)
Other$4,907 (9.4%)
Food & Beverage$2,181 (4.2%)
Education$17.77 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $25,572 | 14 | 49.1% |
| Unspecified | $11,345 | 12 | 21.8% |
| Travel and Lodging | $8,084 | 14 | 15.5% |
| Honoraria | $2,844 | 3 | 5.5% |
| Food and Beverage | $2,181 | 41 | 4.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,063 | 5 | 4.0% |
| Education | $17.77 | 1 | 0.0% |
Payments by Type
General
$40,762
78 transactions
Research
$11,345
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $14,174 | 16 | $0 (2024) |
| Chugai Pharmaceutical Co., Ltd. | $13,837 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $6,545 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $5,898 | 8 | $0 (2019) |
| Helsinn Healthcare SA | $2,363 | 2 | $0 (2020) |
| Daiichi Sankyo Inc. | $1,670 | 3 | $0 (2019) |
| Janssen Global Services, LLC | $1,550 | 1 | $0 (2019) |
| PFIZER INC. | $1,509 | 15 | $0 (2024) |
| Blueprint Medicines Corporation | $1,463 | 1 | $0 (2020) |
| Seagen Inc. | $1,167 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,612 | 27 | Chugai Pharmaceutical Co., Ltd. ($13,837) |
| 2023 | $1,700 | 21 | Seagen Inc. ($1,167) |
| 2022 | $1,436 | 4 | F. Hoffmann-La Roche AG ($1,295) |
| 2021 | $2,500 | 1 | F. Hoffmann-La Roche AG ($2,500) |
| 2020 | $10,922 | 6 | F. Hoffmann-La Roche AG ($5,110) |
| 2019 | $9,904 | 17 | Novartis Pharmaceuticals Corporation ($4,033) |
| 2018 | $4,624 | 10 | AstraZeneca Pharmaceuticals LP ($2,519) |
| 2017 | $1,408 | 4 | F. Hoffmann-La Roche AG ($1,389) |
All Payment Transactions
90 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $589.68 | Research |
| Study: PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC • Category: BioOncology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $532.89 | Research |
| Study: IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIA NSCLC • Category: BioOncology | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 10/31/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,076.67 | General |
| 10/30/2024 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $7,238.59 | General |
| 10/30/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $4,940.00 | General |
| 10/30/2024 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $581.45 | General |
| 10/23/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $608.25 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $647.44 | Research |
| Study: PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC • Category: BioOncology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $589.68 | Research |
| Study: PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC • Category: BioOncology | ||||||
| 09/17/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $10.17 | General |
| 09/17/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $1.53 | General |
| 09/16/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $10.17 | General |
| 09/16/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $1.53 | General |
| 09/15/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $10.17 | General |
| 09/15/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $1.53 | General |
| 09/07/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $88.89 | General |
| 07/03/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $773.50 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $845.92 | Research |
| Study: PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC • Category: BioOncology | ||||||
| 06/04/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $28.73 | General |
| 06/04/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $4.55 | General |
| 06/04/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $2.99 | General |
| 06/03/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $28.73 | General |
| 06/03/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $4.55 | General |
| 06/02/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $4.55 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Association of baseline systemic corticosteroid use with short- and long-term outcomes in patients with advanced non-small cell lung cancer, melanoma, or urothelial carcinoma receiving cancer immunotherapy in real-world US oncology practice | F. Hoffmann-La Roche AG | $3,258 | 1 |
| PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | F. Hoffmann-La Roche AG | $2,673 | 4 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,735 | 2 |
| Association of Baseline Systemic Corticosteroid Use With Time to Next Treatment in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer or Urothelial Cancer Receiving Cancer Immunotherapy in US Clinical Practice | F. Hoffmann-La Roche AG | $1,402 | 1 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $1,295 | 2 |
| IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIA NSCLC | F. Hoffmann-La Roche AG | $532.89 | 1 |
| Association of baseline systemic corticosteroid CS use with time to next treatment TTNT in advanced NSCLC, melanoma and urothelial cancer patients treated with cancer immunotherapy CIT in real world US-based oncology settings | F. Hoffmann-La Roche AG | $449.56 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 167 | 356 | $169,143 | $30,469 |
| 2022 | 3 | 193 | 460 | $200,756 | $41,340 |
| 2021 | 3 | 208 | 525 | $243,579 | $48,202 |
| 2020 | 4 | 233 | 559 | $173,204 | $40,548 |
Total Patients
801
Total Services
1,900
Medicare Billing
$160,559
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 176 | $81,810 | $15,502 | 18.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 30 | 63 | $39,157 | $8,273 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 73 | 117 | $48,176 | $6,694 | 13.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 76 | 253 | $100,484 | $21,581 | 21.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 49 | 113 | $65,006 | $14,385 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 68 | 94 | $35,266 | $5,373 | 15.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 83 | 310 | $131,920 | $27,727 | 21.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 52 | 108 | $67,848 | $14,505 | 21.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 73 | 107 | $43,811 | $5,971 | 13.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 90 | 350 | $92,164 | $24,370 | 26.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 44 | 75 | $28,576 | $7,459 | 26.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 59 | 89 | $24,183 | $4,028 | 16.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $5,922 | $2,499 | 42.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 29 | $22,359 | $2,192 | 9.8% |
About Dr. Heather Wakelee, MD
Dr. Heather Wakelee, MD is a Medical Oncology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1720137094.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Heather Wakelee, MD has received a total of $52,107 in payments from pharmaceutical and medical device companies, with $19,612 received in 2024. These payments were reported across 90 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($25,572).
As a Medicare-enrolled provider, Wakelee has provided services to 801 Medicare beneficiaries, totaling 1,900 services with total Medicare billing of $160,559. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Stanford, CA
- Active Since 01/09/2007
- Last Updated 04/12/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1720137094
Products in Payments
- Tecentriq (Biological) $8,431
- ILARIS (Biological) $3,929
- TAGRISSO (Drug) $3,722
- TECENTRIQ (Biological) $3,685
- TAFINLAR (Drug) $1,735
- Alecensa (Biological) $154.90
- KEYTRUDA (Biological) $141.30
- IMFINZI (Biological) $135.00
- Avastin (Biological) $126.78
- INC280 (Drug) $86.81
- MEKINIST (Drug) $21.91
- LORBRENA (Drug) $17.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Stanford
Sandhya Srinivas, Md, MD
Medical Oncology — Payments: $272,187
Medical Oncology $272,187
Ranjana Advani, Md, MD
Medical Oncology — Payments: $184,712
Medical Oncology $184,712
Kristen Ganjoo, Md, MD
Medical Oncology — Payments: $69,790
Medical Oncology $69,790
Arash Alizadeh, Md, Phd, MD, PHD
Medical Oncology — Payments: $46,821
Medical Oncology $46,821
Gregory Heestand, M.d, M.D
Medical Oncology — Payments: $34,424
Medical Oncology $34,424
Caroline Berube, Md, MD
Medical Oncology — Payments: $30,092
Medical Oncology $30,092